Impact of a mixed bacterial lysate (OM-85 BV) on the immunogenicity, safety and tolerability of inactivated influenza vaccine in children with recurrent respiratory tract infection

Susanna Esposito, Paola Marchisio, Elisabetta Prada, Cristina Daleno, Laura Porretti, Rita Carsetti, Annalisa Bosco, Valentina Ierardi, Alessia Scala, Nicola Principi

Research output: Contribution to journalArticlepeer-review

Abstract

It is known that the immunogenicity and efficacy of conventional inactivated influenza vaccines (IIVs) are not completely satisfactory in children. The aim of this prospective, randomised, single-blind study was to compare the immune response to, and the effectiveness and safety of, an IIV (Fluarix, GlaxoSmithKline Biologicals, Rixensart, Belgium) administered to 68 children aged 36-59 months affected by recurrent respiratory tract infections (RRTIs) who were vaccinated with (n= 33) or without (n= 35) the mixed bacterial lysate OM-85 BV (Broncho-vaxom, Vifor Pharma, Geneva, Switzerland). OM-85 BV had no effect on seroconversion or seroprotection rates, geometric mean titres, or dendritic cells, which were not significantly different between the two groups. Moreover, OM-85 BV did not significantly increase the pool of the memory B cells that produce IgG and IgM antibodies against the influenza antigens. However, respiratory morbidity was significantly lower in the children treated with OM-85 BV (p

Original languageEnglish
Pages (from-to)2546-2552
Number of pages7
JournalVaccine
Volume32
Issue number22
DOIs
Publication statusPublished - May 7 2014

Keywords

  • Bacterial lysate
  • Children
  • Influenza
  • Influenza vaccine
  • OM-85 BV
  • Recurrent respiratory tract infection

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Fingerprint Dive into the research topics of 'Impact of a mixed bacterial lysate (OM-85 BV) on the immunogenicity, safety and tolerability of inactivated influenza vaccine in children with recurrent respiratory tract infection'. Together they form a unique fingerprint.

Cite this